- Mental health tech company Medibio (MEB) has received CE Mark approval for its sleep staging software, MEBsleep
- MEBsleep analyses brain activity and heart rate activity during differing sleep stages in patients suffering sleep disturbances
- It uses artificial intelligence and deep learning algorithms to analyse data to aid the physician in understanding the patient’s condition
- CE Mark approval allows Medibio to commercialise MEBsleep in Europe with a focus on sleep technicians and researchers as the intended users
- Furthermore, the company is in the process of exploring commercialisation paths with European academic groups and pharmaceutical companies
- Medibio is up 11.1 per cent on the back of this news with shares trading at 1 cent
Mental health tech company Medibio (MEB) has received CE Mark approval for its sleep staging software, MEBsleep.
MEBsleep analyses electroencephalogram (EEG) – brain activity – and electrocardiogram (ECG) – heart rate activity – during differing sleep stages in patients suffering sleep disturbances.
It uses artificial intelligence and deep learning algorithms to analyse data and highlight information to aid the physician in understanding the patient’s condition.
The current “top tier” method of assessing sleep disturbances is in a laboratory setting which usually takes 60 to 90 minutes to undertake. MEBsleep performs the same assessment in 60 to 90 seconds.
CE Mark approval allows Medibio to commercialise MEBsleep in Europe with a focus on sleep technicians and researchers as the intended users.
Furthermore, the company is in the process of exploring commercialisation paths with European academic groups and pharmaceutical companies focused on sleep medicine.
“MEBsleep is our first marketable product with CE Mark and its approval is an important step on our path towards commercialisation,” Managing Director Claude Solitario said.
“Furthermore, it is also an important validation as we advise development of our depressive burden software medical device MEB-001, of which MEBsleep is a component,” he added.
Medibio is up 11.1 per cent on the back of this news, with shares trading at 1 cent at 11:33 am AEDT.